Study on the promotion of lymphocytes in patients with COVID-19 by broad-spectrum chemokine receptor inhibitor vMIP-II and its Mechanism of signal transmission in vitro

Ngā tūemi rite

• The viral KSHV chemokine vMIP-II inhibits the migration of Naive and activated human NK cells by antagonizing two distinct chemokine receptors.
  mā: Rachel Yamin, me ētahi atu.
  I whakaputaina: (2013-08-01)
• Study on the promotion of lymphocytes in patients with COVID-19 by broad-spectrum chemokine receptor inhibitor vMIP-II and its Mechanism of signal transmission in vitro
  mā: Shiyu Li, me ētahi atu.
  I whakaputaina: (2021-03-01)
• Expression and Purification of Chemokine MIP-3α (CCL20) through a Calmodulin-Fusion Protein System
  mā: Gopal Ramamourthy, me ētahi atu.
  I whakaputaina: (2019-01-01)
• Chemokines CCL3/MIP1α, CCL5/RANTES and CCL18/PARC are independent risk predictors of short-term mortality in patients with acute coronary syndromes.
  mā: Saskia C A de Jager, me ētahi atu.
  I whakaputaina: (2012-01-01)
• The chemokine MIP1alpha/CCL3 determines pathology in primary RSV infection by regulating the balance of T cell populations in the murine lung.
  mā: John S Tregoning, me ētahi atu.
  I whakaputaina: (2010-02-01)